Research studies employing transcriptomic analysis have demonstrated that TILs are positively associated with an enhanced anti-tumor immunity in ER-positive/HER2-negative breast cancer subtypes, as well as with better overall survival in HER2-positive and TNBC subtypes (122). The gene discussed is ESR1; the disease is neoplasm.